1. Abbruzzese A, Swanson J: Jaundice after therapy with chlordiazepoxide hydrochloride. N Engl J Med 273: 321-322, 1965.

2. Ajdukiewicz AB, Grainger J, Scheuer PJ, Sherlock S: Jaundice due to iprindole. Gut 12: 705-708, 1971.

3. Al-Kawas FH, Seeff LB, Berendson RA, et al: Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med 95: 588-590, 1981.

4. Ammann R, Neftel K, Hardmeier T, et al: Cephalosporin-induced cholestatic jaundice. Lancet 2: 336-337, 1982.

5. Anthony PP: Liver tumors. Baillière's Clin Gastroenterol 2: 501-522, 1988.

6. Aponte J, Petrelli M: Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate. Arthritis Rheumatol 31: 1457-1461, 1988.

7. Arranto AJ, Sotaniemi EA: Morphologic alterations in patients with alpha-methyldopa-induced liver damage after short- and long-term exposure. Scand J Gastroenterol 16: 853-863, 1981.

8. Babany G, Uzzan F, Larrey D, et al: Alcoholic-like liver lesions induced by nifedipine. J Hepatol 9: 252-255, 1989.

9. Bach N, Thung SN, Schaffner F, Tobias H: Exaggerated cholestasis and hepatic fibrosis following simulaneous administration of chlorpromazine and sodium valproate. Dig Dis Sci 34: 1303-1307, 1989.

10. Baker AL, Rosenberg IH: Hepatic complications of total parenteral nutrition. Am J Med 82: 489-497, 1987.

11. Balistreri WF, Bove KE: Hepatobiliary consequences of parenteral alimentation. Prog Liv Dis 9: 567-601, 1990.

12. Barnard JA, Marshall GS, Neblett WW, et al: Noncirrhotic portal fibrosis after Wilms' tumor therapy. Gastroenterology 90: 1054-1056, 1986.

13. Bartle WR, Fisher MM, Kerenyi N: Disulfiram-induced hepatitis: Report of two cases and review of the literature. Dig Dis Sci 30: 834-837, 1985.

14. Bassendine MF, Woodhouse KW, Bennett M, James OFW: Dextropropoxyphene induced hepatotoxicity mimicking biliary tract disease. Gut 27: 444-449, 1986.

15. Bellary SV, Isaacs PET, Scott AWM: Captopril and the liver. Lancet 2: 514, 1989.

16. Benjamin SB, Goodman ZD, Ishak KG, et al: The morphologic spectrum of halothane-induced hepatic injury. Hepatology 5: 1163-1171, 1985.

17. Benjamin SB, Ishak KG, Zimmerman HJ, Grushka A: Phenylbutazone liver injury: A clinical-pathologic survey of 23 cases and review of the literature. Hepatology 1: 255-263, 1981.

18. Bercoff E, Bernuau J, Degott C, et al: Ketoconazole-induced fulminant hepatitis. Gut 26: 636-638, 1985.

19. Bianchi L, De Groote J, Desmet V, et al: Guidelines for diagnosis of therapeutic drug-induced liver injury in liver biopsies. Lancet 1: 854-857, 1974.

20. Bioulac-Sage P, Quinton A, Saric J, et al: Chance discovery of hepatic fibrosis in patient with asymptomatic hypervitaminosis A. Arch Pathol Lab Med 112: 505-509, 1988.

21. Bjorkman DJ, Hammond EH, Lee RG, et al: Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheumatol 31: 1465-1472, 1988.

22. Black M: Acetaminophen hepatotoxicity. Ann Rev Med 35: 577-593, 1984.

23. Black M, Cornell JF, Rabin L, Shachter N: Late presentation of acetaminophen hepatotoxicity. Dig Dis Sci 27: 370-374, 1982.

24. Black M, Mitchell JR, Zimmerman HJ, et al: Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69: 289-302, 1975.

25. Blackburn AM, Amiel SA, Millis RR, Rubens RD: Tamoxifen and liver damage. Br Med J 289: 288, 1984.

26. Blom H, Stolk J, Schreuder HB, et al: A case of carbimazole-induced intrahepatic cholestasis. An immune-mediated reaction? Arch Intern Med 145: 1513-1514, 1985.

27. Bowyer BA, Fleming CR, Ludwig J, et al: Does long-term home parenteral nutrition in adult patients cause chronic liver disease? JPEN 9: 11-17, 1985.

28. Bradfeldt JE, Havey AL: Nodular regenerative hyperplasia of the liver following renal transplantation. Dig Dis Sci 26: 271-274, 1981.

29. Bramlet DA, Posalaky Z, Olson R: Granulomatous hepatitis as a manifestation of quinidine hypersensitivity. Arch Intern Med 140: 395-397, 1980.

30. Bridges ME, Pittman FE: Tolazamide-induced cholestasis. South Med J 73: 1072-1074, 1980.

31. Brown PJE, Lesna M, Hamlyn AN, Record CO: Primary biliary cirrhosis after long-term practolol administration. Br Med J 1: 1591, 1976.

32. Bruckstein AH, Attia AA: Oxacillin hepatitis. Two patients with liver biopsy, and review of the literature. Am J Med 64: 519-522, 1978.

33. Bruguera M, Lamar C, Bernet M, Rodés J: Hepatic disease associated with ground-glass inclusions in hepatocytes after cyanamide therapy. Arch Pathol Lab Med 110: 906-910, 1986.

34. Bruguera M, Pares A, Heredia D, Rodés J: Cyanamide hepatotoxicity. Incidence and clinical-pathological features. Liver 7: 216-222, 1987.

35. Bui HD, Chaney RH: Transient hepatitis due to low dose neuroleptic medication. Am J Gastroenterol 84: 578-579, 1989.

36. Burgunder J-M, Abernethy DR, Lauterburg BH: Liver injury due to verapamil. Hepato-gastroenterol 35: 169-170, 1988.

37. Caballeria E, Masso RM, Arago JV, et al: Piroxicam hepatotoxicity. Am J Gastroenterol 85: 898-899, 1990.

38. Cacace LG, Cohen M: Alpha-methyldopa (Aldomet) hepatitis. Report of a case and review of the literature. Drug Intell Clin Pharmacol 10: 144-152, 1976.

39. Camuto P, Shupack J, Orbuch P, et al: Long-term effects of etretinate on the liver in psoriasis. Am J Surg Pathol 11: 30-37, 1987.

40. Carrasco D, Prieto M, Pallardo L, et al: Multiple hepatic adenomas after longterm therapy with testosterone enanthate. Review of the literature. J Hepatol 1: 573-578, 1985.

41. Cavanzo FJ, Garcia CF, Botero RC: Chronic cholestasis, paucity of bile ducts, red cell aplasia, and the Stevens-Johnson syndrome. An ampicillin-associated case. Gastroenterology 99: 854-856, 1990.

42. Ceci G, Bella M, Melissari M, et al: Fatal hepatic vascular toxicity of DTIC. Cancer 61: 1988-1991, 1988.

43. Chiprut RO, Viteri A, Jamroz C, Dyck WP: Intrahepatic cholestasis after griseofulvin administration. Gastroenterology 70: 1141-1143, 1976.

44. Clark JA, Zimmerman HJ, Tanner LA: Labetalol hepatotoxicity. Ann Intern Med 113: 210-213, 1990.

45. Cobden I, Record CO, White RWB: Fatal intrahepatic cholestasis associated with triazolam. Postgrad Med J 57: 730-731, 1981.

46. Cohen C: Liver pathology in hycanthone hepatitis. Gastroenterology 75: 103-106, 1978.

47. Cohen C, Olsen MM: Pediatric total parenteral nutrition. Liver histopathology. Arch Pathol Lab Med 105: 152-156, 1981.

48. Craig RM, Neumann T, Jeejeebhoy KN, Yokoo H: Severe hepatocellular reaction resembling alcoholic hepatitis with cirrhosis after massive small bowel resection and prolonged total parenteral nutrition. Gastroenterology 79: 131-137, 1980.

49. Dahms BB, Halpin TC Jr: Serial liver biopsies in parenteral nutrition-associated cholestasis of early infancy. Gastroenterology 81: 136-144, 1981.

50. Danan G, Bernuau J, Moullot X, et al: Amitriptyline-induced fulminant hepatitis. Digestion 30: 179-184, 1984.

51. Davis M, Eddleston AL, Williams R: Hypersensitivity and jaundice due to azathioprine. Postgrad Med J 56: 274-277, 1980.

52. D'Cruz CA, Wimmer RS, Harcke HT, et al: Veno-occlusive disease of the liver in children following chemotherapy for acute myelocytic leukemia. Cancer 52: 1803-1807, 1983.

52a. Degott C, Feldmann G, Larrey D, et al: Drug-induced prolonged cholestasis in adults: A histological semiquantitative study demonstrating progressive ductopenia. Hepatology 15: 244-251, 1992.

53. Degott C, Messing B, Moneau D, et al: Liver phospholipidosis induced by parenteral nutrition: Histologic, histochemical and ultrastructural investigations. Gastroenterology 95: 183-191, 1988.

54. Degott C, Rueff B, Kreis H, et al: Peliosis hepatis in recipients of renal transplants. Gut 19: 748-753, 1978.

55. DeGroot H, Noll T: Halothane hepatotoxicity: Relation between metabolic activation, hypoxia, covalent binding, lipid peroxidation and liver cell damage. Hepatology 3: 601-606, 1983.

56. Dejgaard A, Krogsgaard K, Jacobsen M: Veno-occlusive disease and peliosis of the liver after thorotrast administration. Virchows Arch [A] 403: 87-94, 1984.

57. De Pinho R, Goldberg CS, Lefkowitch JH: Azathioprine and the liver. Evidence favoring idiosyncratic mixed cholestatic-hepatocellular injury in humans. Gastroenterology 86: 162-165, 1984.

58. Dhand AKK, LaBrecque DR, Metzger J: Sulindac (clinoril) hepatitis. Gastroenterology 80: 585-586, 1981.

59. Diehl AM, Latham P, Boitnott JK, et al: Cholestatic hepatitis from erythromycin ethylsuccinate. Report of two cases. Am J Med 76: 931-934, 1984.

60. Dincsoy HP, Saelinger DA: Haloperidol-induced chronic cholestatic liver disease. Gastroenterology 83: 694-700, 1982.

61. Doria MI Jr, Shepard KV, Levin B, Riddell RH: Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR. Cancer 58: 855-861, 1986.

62. Døssing M, Andreasen PB: Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs. Scand J Gastroenterol 17: 205-211, 1982.

63. Dreifuss FE, Langer DH, Moline KA, Maxwell JE: Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 39: 201-207, 1989.

64. Eadie MJ, Hooper WD, Dickinson RG: Valproate-associated hepatotoxicity and its biochemical mechanisms. Med Toxicol 3: 85-106, 1988.

65. Eger EI, Smuckler EA, Ferrell LD, et al: Is enflurane hepatotoxic? Anesth Analg 65: 21-26, 1986.

66. Enat R, Pollack S, Ben-Arieh Y, et al: Cholestatic jaundice caused by cloxacillin: Macrophage inhibition factor test in preventing and rechallenge with hepatotoxic drugs. Br Med J 280: 982-983, 1980.

67. Etchason JA, Miller TD, Squires RW, et al: Niacin-induced hepatitis: A potential side effect with low-dose time-release niacin. Mayo Clin Proc 66: 23-28, 1991.

68. Farrell G, Prendergast D, Murray M: Halothane hepatitis. Detection of a constiutional susceptibility factor. N Engl J Med 313: 1310-1313, 1985.

69. Fermand JP, Levy Y, Bouscary D, et al: Danazol-induced hepatocellular adenoma. Am J Med 88: 529-530, 1990.

70. Fich A, Schwartz J, Braverman D, et al: Sulfasalazine hepatotoxicity. Am J Gastroenterol 79: 401-402, 1984.

71. Fisher RL, Anderson DW, Boyer JL, et al: A prospective morphologic evaluation of hepatic toxicity of chenodeoxycholic acid in patients with cholelithiasis: The National Cooperative Gallstone Study. Hepatology 2: 187-201, 1982.

72. Forman D, Vincent TJ, Doll R: Cancer of the liver and use of oral contraceptives. Br Med J 292: 1357-1361, 1986.

73. Foulis PR, Sandford BH, Gottfried M: Drug induced morphologic changes in the liver. Ann Clin Lab Sci 18: 215-228, 1988.

74. Gaffey CM, Chun B, Harvey JC, et al: Phenytoin-induced systemic granulomatous vasculitis. Arch Pathol Lab Med 110: 131-135, 1986.

75. Gan TE, van der Weyden MB: Dapsone-induced infectious mononucleosis-like syndrome. Med J Aust 1: 350-351, 1982.

76. Gerber MA, Kaufmann H, Klion F, Alpert LI: Acetaminophen associated hepatic injury. Report of two cases showing unusual portal tract reactions. Hum Pathol 11: 37-42, 1980.

77. Gerlag PGG, Lobatto S, Driessen WMM, et al: Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment after kidney transplantation. J Hepatol 1: 339-348, 1985.

78. Geubel AP, DeGalocsy C, Alves N, et al: Liver damage caused by therapeutic vitamin A administration: Estimate of dose-related toxicity in 41 cases. Gastroenterology 100: 1701-1709, 1991.

79. Geubel AP, Nakad A, Rahier J, Dive C: Prolonged cholestasis and disappearance of interlobular bile ducts following chlorpropamide and erythromycin ethylsuccinate. Case of drug interaction? Liver 8: 350-353, 1988.

80. Ghishan FK, LaBrecque DR, Younoszai K: Intrahepatic cholestasis after gold therapy in juvenile rheumatoid arthritis. J Pediatr 93: 1042-1043, 1978.

81. Gholson CF, Warren GH: Fulminant hepatic failure associated with intravenous erythomycin lactobionate. Arch Intern Med 150: 215-216, 1990.

82. Giarelli L, Falconieri G, Delendi M: Fulminant hepatitis following naproxen administration. Hum Pathol 17: 1079, 1986.

83. Gilbert SC, Klintmalm G, Menter A, Silverman A: Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agent. Arch Intern Med 150: 889-891, 1990.

84. Gill RA, Onstad GR, Cardamone JM, et al: Hepatic veno-occlusive disease caused by 6-thioguanine. Ann Intern Med 96: 58-60, 1982.

85. Glazer SD, Roenigk HH Jr, Yokoo H, Sparburg M: A study of potential hepatotoxicity of etretinate used in the treatment of psoriasis. J Am Acad Dermatol 6: 683-687, 1982.

86. Glober GA, Wilkerson JA: Biliary cirrhosis following the administration of methyltesterone. JAMA 204: 170-173, 1968.

87. Goldfinger SE, Marx S: Hypersensitivity hepatitis due to phenazopyridine hydrochloride. N Engl J Med 286: 1090-1091, 1972.

88. Goldman IS, Winkler ML, Raper SE, et al: Increased hepatic density and phospholipidosis due to amiodarone. AJR 144: 541-546, 1985.

89. Goldstein MJ, Rothenberg AJ: Jaundice in a patient receiving acetohexamide. N Engl J Med 275: 97-99, 1966.

90. Goodman RC, Dean PJ, Radparvar A, Kitabchi AE: Glyburide-induced hepatitis. Ann Intern Med 106: 837-839, 1987.

91. Goodman ZD, Ishak KG: Hepatocellular carcinoma in women: Probable lack of etiologic association with oral contraceptives steroids. Hepatology 2: 440-444, 1982.

92. Gottfried MR, Sudilovsky O: Hepatic veno-occlusive disease after high dose mitomycin C and autologous bone marrow transplantation therapy. Hum Pathol 13: 646-650, 1982.

93. Greenstone MA, Dowd PM, MIkhailidis DP, et al: Hepatic vascular lesions associated with dacarbazine treatment. Br Med J 282: 1744-1745, 1981.

94. Gregory DH, Zaki GF, Sarcosi GA, Carey JB Jr: Chronic cholestasis following prolonged tolbutamide administration. Associated with destructive cholangitis and cholangiolitis. Arch Pathol 84: 194-201, 1967.

95. Guarascio P, d'Amato C, Sette P, et al: Liver damage from verapamil. Br Med J 288: 362-363, 1984.

96. Guarascio P, Portmann B, Visco G, Williams R: Liver damage with reversible portal hypertension from vitamin A intoxication: demonstration of Ito cells. J Clin Pathol 36: 759-771, 1983.

97. Guigui B, Perrot S, Berry JP, et al: Amiodarone-induced hepatic phospholipidosis: A morphological alteration independent of pseudoalcoholic liver disease. Hepatology 8: 1063-1068, 1988.

98. Haboubi NY, Ali HH, Whitwell HL, Ackrill P: Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: Light microscopy and ultrastructural observations. Am J Gastroenterol 83: 256-261, 1988.

99. Hamlyn AN, Morris JS, Sarkany I, Sherlock S: Piperazine hepatitis. Gastroenterology 70: 1144-1147, 1976.

100. Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76: 47-56, 1984.

101. Hanson JS: Propylthiouracil and hepatitis. Two cases and a review of the literature. Arch Intern Med 144: 994-996, 1984.

102. Harats N, Ehrenfeld M, Cleuckauf LG, Lutin JJ: Gold-induced granulomatous hepatitis. Isr J Med Sci 21: 753-756, 1985.

103. Hare DL, Horowitz JD: Verapamil hepatotoxicity: A hypersensitivity reaction. Am Heart J 111: 610-615, 1986.

104. Health and Public Policy Committee, American College of Physicians: Methotrexate in rheumatoid arthritis. 107: 418-419, 1987.

105. Hepps K, Maliha G, Estrada R, et al: Severe cholestatic jaundice associated with piroxicam. Gastroenterology 101: 1737-1740, 1991.

106. Herlong HF, Reid PR, Boitnott JK, Maddrey WC: Aprindine hepatitis. Ann Intern Med 89: 359-361, 1978.

107. Hohn D, Melnick J, Stagg R, et al: Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 3: 98-102, 1985.

108. Hopwood D, Nyfors A: Effect of methotrexate therapy in psoriatics on the Ito cells in liver biopsies, assessed by point-counting. J Clin Pathol 29: 698-703, 1976.

109. Horst DA, Grace ND, LeCompte PM: Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy. Gastroenterology 79: 550-554, 1980.

110. Huggins GR, Zucker PK: Oral contraceptives and neoplasia: 1987 update. Fertil Steril 47: 733-761, 1987.

111. Ishak KG: Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1: 116-128, 1981.

112. Ishak KG: The liver. In Riddell RH (ed): Pathology of Drug-induced and Toxic Diseases. New York, 1982, Churchill Livingstone. pp. 457-513.

113. Ishak KG, Irey NS: Hepatic injury associated with the phenothiazines. Clinico-pathologic and follow-up study of 36 patients. Arch Pathol 93: 283-304, 1972.

114. Ishak KG, Kirchner JP, Dhar JK: Granulomas and cholestatic-hepatocellular injury associated with phenylbutazone. Report of two cases. Am J Dig Dis 22: 611-617, 1977.

115. Ishak KG, Mullick FG: Drug-induced and toxic liver injury. In Peters RL, Craig JR: Liver Pathology. Contemporary issues in surgical pathology, vol 8. New York, 1986, Churchill Livingstone. pp. 221-254.

116. Ishak KG, Zimmerman HJ: Drug-induced and toxic granulomatous hepatitis. Baillière's Clin Gastroenterol 2: 463-480, 1988.

117. Ishak KG, Zimmerman HJ: Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liv Dis 7: 230-236, 1987.

118. Ito Y, Kojiro M, Nakashima T, Mori T: Pathomorphologic characteristics of 102 cases of thorotrast-related hepatocellular carcinoma, cholangiocarcinoma, and hepatic angiosarcoma. Cancer 62: 1153-1162, 1988.

119. Itoh S, Igarashi M, Tsukada Y, Ichinoe A: Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy. Acta Hepato-gastroenterol 24: 415-418, 1977.

120. Itoh S, Yamaba Y, Ichinoe A, Tsukada Y: Hydralazine-induced liver injury. Dig Dis Sci 25: 884-887, 1980.

121. Iveson TJ, Ryley NG, Kelly PMA, et al: Diclofenac-associated hepatitis. J Hepatol 10: 85-89, 1990.

122. Jacobs MB: Hepatic infarction related to oral contraceptive use. Arch Intern Med 144: 642-643, 1984.

123. Jacques EA, Buschmann RJ, Layden TJ: The histopathologic progression of vitamin A-induced hepatic injury. Gastroenterology 76: 599-602, 1979.

124. Jayalakshmi P, Ting HC: Dapsone-induced liver necrosis. Histopathology 17: 89-91, 1990.

125. Jick H, Walker AM, Porter J: Drug-induced liver disease. J Clin Pharmacol 21: 359-364, 1981.

126. Johnson DA, Cattau EL, Kuritsky JN, Zimmerman HJ: Liver involvement in the sulfone syndrome. Arch Intern Med 146: 875-877, 1986.

127. Johnson DH, Greco FA, Wolff SN: Etoposide-induced hepatic injury: A potential complication of high-dose therapy. Cancer Treat Rep 67: 1023-1024, 1983.

128. Johnson GK, Tolman KG: Chronic liver disease and acetominophen. Ann Intern Med 87: 302-304, 1977.

129. Jones DB, Mullick FG, Hoofnagle JH, Baranski B: Reye's syndrome-like illness in a patient receiving amiodarone. Am J Gastroenterol 83: 967-970, 1988.

130. Joshi PH, Conn HO: The syndrome of methoxyflurane-associated hepatitis. Ann Intern Med 80: 395-401, 1974.

131. Kahan BD, Flechner SM, Lorber MI, et al: Complications of cyclosporin therapy. World J Surg 10: 348-360, 1986.

132. Kahn H, Manzarbeitia C, Theise N, et al: Danazol-induced hepatocellular adenoma. A case report and review of the literature. Arch Pathol Lab Med 115: 1054-1057, 1991.

133. Kalantzis N, Gabriel P, Mouzas J, et al: Acute amiodarone-induced hepatitis. Hepatogastroenterology 38: 71-74, 1991.

134. Kanel GC, Cassidy W, Shuster L, et al: Cocaine-induced liver cell injury: Comparison of morphologic features in man and in experimental models. Hepatology 11: 646-651, 1990.

135. Kaplowitz N, Aw TY, Simon FR, Stolz A: Drug-induced hepatotoxicity. Ann Intern Med 104: 826-839, 1986.

136. Kassianides C, Nussenblatt R, Palestine AG, et al: Liver injury from cyclosporine A. Dig Dis Sci 35: 693-697, 1990.

137. Katzka DA, Saul SH, Jorkasky D, et al: Azathioprine and hepatic venoocclusive disease in renal transplant patients. Gastroenterology 90: 446-454, 1986.

138. Kenna JG, Satoh H, Christ DD, Pohl LR: Metabolic basis for drug hypersensitivity: Antibodies in sera of patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exper Therap 245: 1103-1109, 1988.

139. Klein AS, Hart J, Brems JJ, et al: Amanita poisoning: Treatment and the role of liver transplantation. Am J Med 86: 187,193, 1989.

140. Klintmalm GBG, Iwatsuki S, Starzl TE: Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation 32: 488-489, 1981.

141. Knobler H, Levij IS, Gavish D, et al: Quinidine-induced hepatitis. A common and reversible hypersensitivity reaction. Arch Intern Med 146: 526-527, 1986.

142. Koch HK, Gropp A, Oehlert W: Drug-induced liver injury in liver biopsies of the years 1981 and 1983, their prevalence and type of presentation. Path Res Pract 179: 469-477, 1985.

143. Kowdley KV, Keeffe EB, Fawaz KA: Prolonged cholestasis due to trimethroprim sulfamethoxazole. Gastroenterology 102: 2148-2150, 1992.

144. Kremer JM, Lee RG, Tolman KG: Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy: A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 32: 121-127, 1989.

145. Kronborg IJ, Evans DT, Mackay IR, Bhathal PS: Chronic hepatitis after successive halothane administrations. Digestion 27: 123-128, 1983.

146. Labadie H, Stoessel P, Callard P, Beaugrand M: Hepatic venoocclusive disease and perisinusoidal fibrosis secondary to arsenic poisoning. Gastroenterology 99: 140-1143, 1990.

147. Lanse SB, Arnold GL, Gowans JDC, et al: Low incidence of hepatotoxicity associated with long-term low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. Dig Dis Sci 30: 104-109, 1985.

148. Larrey D, Amouyal G, Pessayre D,et al: Amitriptyline-induced prolonged cholestasis. Gastroenterology 94: 200-203, 1988.

149. Larrey D, Erlinger S: Drug-induced cholestasis. Baillière's Clin Gastroenterol 2: 423-452, 1988.

150. Larrey D, Fréneaux E, Berson A, et al: Peliosis hepatis induced by 6-thioguanine administration. Gut 29: 1265-1269, 1988.

151. Larrey D, Hadengue A, Pessayre D, et al: Carbamazepine-induced acute cholangitis. Dig Dis Sci 32: 554-557, 1987.

152. Larrey D, Pessayre D, Duhamel G, et al: Prolonged cholestasis after ajmaline-induced acute hepatitis. J Hepatol 2: 81-87, 1986.

153. Lee MG, Hanchard B, Williams NP: Drug-induced acute liver disease. Postgrad Med J 65: 367-370, 1989.

154. Lee SM, O'Brien CJ, Williams R, et al: Subacute hepatic necrosis induced by piroxicam. Br Med J 293: 540-541, 1986.

155. Leo MA, Lieber CS: Hypervitaminosis A: A liver lover's lament. Hepatology 8: 412-417, 1988.

156. Lerche A, Vyberg M, Kirkegaard E: Acute cholangitis and pancreatitis associated with sulindac (Clinoril). Histopathology 11: 647-653, 1987.

158. Lewis JH, Mullick F, Ishak KG, et al: Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 21: 59-67, 1990.

159. Lewis JH, Ranard RC, Caruso A, et al: Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients. Hepatology 9: 679-685, 1989.

160. Lewis JH, Schiff E: Methotrexate-induced chronic liver injury: Guidelines for detection and prevention. Am J Gastroenterol 88: 1337-1345, 1988.

161. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG: Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 86: 503-513, 1984.

162. Lewis JH, Zimmerman HJ, Ishak KG, Mullick FG: Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Intern Med 98: 984-992, 1983.

163. Liaw Y-F, Huang M-J, Fan K-D, et al: Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med 118: 424-428, 1993.

164. Lieberman DA, Keeffe EB, Stenzel P: Severe and prolonged contraceptive jaundice. J Clin Gastroenterol 6: 145-148, 1984.

165. Limaye A, Ruffolo PR: Propylthiouracil-induced fatal hepatic necrosis. Am J Gastroenterol 82: 152-155, 1987.

166. Littlewood E, Barrison I, Murray-Lyon IM, Pradinus FJ: Cholangiocarcinoma and oral contraceptives. Lancet 1: 310-311, 1980.

167. Loomus GN, Aneja P, Bota RA: A case of peliosis hepatis in association with tamoxifen therapy. Am J Clin Pathol 80: 881-883, 1983.

168. Lorenzini I, Jezequel AM, Orlandi F: Cimetidine-induced hepatitis. Electron microscopic observations and clinical pattern of liver injury. Dig Dis Sci 26: 275-280, 1981.

169. Ludwig J, Axelsen R: Drug effects on the liver. An updated tabular compilation of drugs and drug-related hepatic diseases. Dig Dis Sci 38: 651-666, 1983.

170. Maddrey WC: Isoniazid-induced liver disease. Semin Liv Dis 1: 129-133, 1981.

171. Maddrey WC, Boitnott JK: Drug-induced chronic liver disease. Gastroenterology 72: 1348-1353, 1977.

172. Manivel JC, Bloomer JR, Snover DC: Progressive bile duct injury after thiobendazole administration. Gastroenterology 93: 245-249, 1987.

173. Marubbio AT, Danielson B: Hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine. Gastroenterology 69: 739-743, 1975.

174. Mathur S, Dooley J, Scheuer PJ: Quinine induced granulomatous hepatitis and vasculitis. Br Med J 300: 613, 1990.

175. McCaughan GW, Bilous MJ, Gallagher ND: Long-term survival with tumour regression in androgen-induced liver tumors. Cancer 56: 2622-2626, 1985.

176. McDonald GB, Hinds MS, Fisher LD, et al: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 118: 255-267, 1993.

177. McDonald GB, Sharma P, Matthews DE, et al: Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 4: 116-112, 1984.

178. McGill DB, Motto JD: An industrial outbreak of toxic hepatitis due to methylenedianiline. N Engl J Med 291: 278-282, 1974.

179. McIntyre RE, Magidson JG, Austin GE, Gale RP: Fatal veno-occlusive disease of the liver following high-dose 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and autologous bone marrow transplantation. Am J Clin Pathol 75: 614-617, 1981.

180. McMaster KR III, Hennigar GR: Drug-induced granulomatous hepatitis. Lab Invest 44: 61-73, 1981.

181. Messing B, Bories C, Kunstlinger F, Bernier J-J: Does total parenteral nutrition induced gallbladder sludge formation and lithiasis? Gastroenterology 84: 10121-1019, 1983.

182. Minuk GY, Kelly JK, Hwang W-S: Vitamin A hepatotoxicity in multiple family members. Hepatology 8: 272-275, 1988.

183. Mion F, Napoleon B, Berger F, et al: Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 32: 715-717, 1991.

184. Mitchell JR, Zimmerman HJ, Ishak KG, et al: Isoniazid liver injury. Clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 84: 181-192, 1976.

185. Mitchell MC, Boitnott JK, Arregui A, et al: Granulomatous hepatitis associated with carbamazepine therapy. Am J Med 71: 733-735, 1981.

186. Mitchell MC, Boitnott JK, Kaufman S, et al: Budd-Chiari syndrome: Etiology, diagnosis and management. Medicine 61: 199-218, 1982.

187. Mockli G, Crowley M, Stern R, Warnock ML: Massive hepatic necrosis in a child after administration of phenobarbital. Am J Gastroenterol 84: 820-824, 1989.

188. Monroe P, Riddell R, Siegler M, Baker A: Hepatic angiosarcoma. Possible relationship to long-term oral contraceptive ingestion. JAMA 246: 64-65, 1981.

189. Mori H, Tanaka T, Sugie S, Takhashi M: Adenoma with multiple hyperplastic nodules in noncirrhotic liver possibly related to long-term administration of a hypolipidemic drug. Acta Pathol Jpn 32: 671-675, 1982.

190. Morris JS, Schmid M, Newman S, et al: Arsenic and noncirrhotic portal hypertension. Gastroenterology 66: 86-94, 1974.

191. Moulding TS, Redeker A, Kanel GC: Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis 140: 700-705, 1989.

192. Mullick FG, Ishak KG: Hepatic injury associated with diphenylhydantoin therapy. A clinicopathologic study of 20 cases. Am J Clin Pathol 74: 442-452, 1980.

193. Mullick FG, Ishak KG, Mahabir R, Stromeyer FW: Hepatic injury associated with paraquat toxicity in humans. Liver 1: 209-221, 1981.

194. Mullick FG, McAllister HA Jr, Wagner BM, Fenoglio JJ Jr: Drug related vasculitis. Clinicopathologic correlations in 30 patients. Hum Pathol 10: 313-325, 1979.

195. Mullin GE, Greenson JK, Mitchell MC: Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 111: 253-255, 1989.

196. Multz CV: Cholestatic hepatitis caused by penicillamine. JAMA 246: 674-675, 1981.

197. Munoz SJ, Martinez-Hernandez A, Maddrey WC: Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim sulfamethoxazole. Hepatology 12: 342-347, 1990.

198. Myers JL, Augur NA Jr: Hydralazine-induced cholangitis. Gastroenterology 87: 1185-1188, 1984.

199. Nadell J, Kosek J: Peliosis hepatis. Twelve cases associated with oral androgen therapy. Arch Pathol Lab Med 101: 405-410, 1977.

200. Nair SS, Kaplan JM, Levine LH, Geraci K: Trimethoprim-sulfamethoxazole-induced intraheptic cholestasis. Ann Intern Med 92: 511-512, 1980.

201. Nakao NL, Gelb AM, Stenger RJ, et al: A case of chronic liver disease due to tolazamide. Gastroenterology 89: 192-194, 1985.

202. Nakhleh RE, Wesen C, Snover DC, Grage T: Venoocclusive lesions of the central veins and portal vein radicles secondary to intraarterial 5-fluoro-2'-deoxyuridine infusion. Hum Pathol 20: 1218-1220, 1989.

203. Namias A, Bhalotra R, Donowitz M: Reversible sulfasalazine-induced granulomatous hepatitis. J Clin Gastroenterol 3: 193-198, 1981.

204. Nässberger L: Disulfiram-induced hepatitis -- report of a case and review of the literature. Postgrad Med J 60: 639-641, 1984.

205. Nesher G, Dollberg L, Zimran A, et al: Hepatosplenic peliosis after danazol and glucocorticoids for ITP. N Engl J Med 312: 242-243, 1985.

206. Neuberger J, Forman D, Doll R, Williams R: Oral contraceptives and hepatocellular carcinoma. Br Med J 292: 1355-1357, 1986.

207. Neuberger JM, Williams R: Halothane anesthesia and liver damage. Br Med J 289: 1136-1141, 1984.

208. Noseda A, Borsch G, Muller K-M, et al: Methimazole-associated cholestatic liver injury: Case report and brief literature review. Hepato-gastroenterol 33: 244-247, 1986.

209. Nyfors A, Poulsen H: Morphogenesis of fibrosis and cirrhosis in methotrexate-treated patients with psoriasis. Am J Surg Pathol 1: 235-243, 1977.

210. Ozenne G, Manchon ND, Doucet J, et al: Carbimazole-induced acute cholestatic hepatitis. J Clin Gastroenterol 11: 95-98, 1989.

211. Pagliaro L, Campesi G, Aguglia F: Barbiturate jaundice. Report of a case due to a barbital-containing drug, with positive rechallenge to phenobarbital. Gastroenterology 56: 938-943, 1969.

212. Paliard P, Vitrey D, Fournier G, et al: Perhexiline maleate-induced hepatitis. Digestion 17: 419-427, 1978.

213. Pariente EA, Pessayre D, Bernuau J, et al: Dihydralazine hepatitis. Report of a case and review of the literature. Digestion 27: 47-52, 1983.

214. Park GD, Spector R, Headstream T, Goldberg M: Serious adverse reactions associated with sulindac. Arch Intern Med 142: 1292-1294, 1982.

215. Pathy MS, Reynolds AJ: Papaverine and hepatotoxicity. Postgrad Med J 56: 488-490, 1980.

216. Perino LE, Warren GH, Levine GS: Cocaine-induced hepatotoxicity in humans. Gastroenterology 93: 176-180, 1987.

217. Perry MC: Chemotherapeutic agents and hepatotoxicity. Semin Oncol 19: 551-565, 1992.

218. Pessayre D: Mechanisms of drug-induced hepatic injury. In Stricker BHC (ed): Drug-induced Hepatic Injury, 2nd ed. Amsterdam, 1992, Elsevier Science Publishers.

219. Pessayre D, Bichara M, Feldmann G, et al: Perhexiline maleate-induced cirrhosis. Gastroenterology 76: 170-177, 1979.

220. Pessayre D, Degos F, Feldmann G, et al: Chronic active hepatitis and giant multinucleated giant cells in adults treated with clometacin. Digestion 22: 66-72, 1981.

221. Pessayre D, De Saint-Louvent P, Degott C, et al: Iproclozide fulminant hepatitis. Possible role of enzyme induction. Gastroenterology 75: 492-496, 1978.

222. Pessayre D, Larrey D: Acute and chronic drug-induced hepatitis. Baillière's Clin Gastroenterol 2: 385-422, 1988.

223. Peters RL, Edmondson HA, Mikkelsen WP, et al: Tetracycline-induced fatty liver in non-pregnant patients. Am J Surg 113: 622-632, 1967.

224. Pettavel J, Gardiol D, Bergier N, et al: Fatal liver cirrhosis associated with long-term arterial infusion of floxuridine. Lancet 2: 1162-1163, 1987.

225. Pizzuto J, Aviles A, Ramos E, et al: Cytosine arabinoside induced liver damage: Histopathologic demonstration. Med Pediatr Oncol 11: 287-290, 1983.

226. Planas R, DeLeon R, Quer JC, et al: Fatal submassive necrosis of the liver associated with piroxicam. Am J Gastroenterol 85: 468-470, 1990.

227. Podurgiel BJ, McGill DB, Ludwig J, et al: Liver injury associated with methotrexate therapy with psoriasis. Mayo Clin Proc 48: 787-792, 1973.

228. Poncin E, Silvain C, Touchard G, et al: Papervine-induced chronic liver disease. Gastroenterology 90: 1051-1053, 1986.

229. Pond SM: Effects on the liver of chemical encountered in the workplace. West J Med 137: 506-514, 1982.

230. Portmann B, Talbot IC, Day DW, et al: Histopathological changes in the liver following a paracetamol overdose: Correlation with clinical and biochemical parameters. J Pathol 117: 169-181, 1975.

231. Poucell S, Ireton J, Valencia-Mayoral P, et al: Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 86: 926-936, 1984.

232. Poupon R, Rosensztajn L, Prudhomme de Saint Maur P, et al: Perhexiline maleate-associated hepatic injury. Prevalence and characteristics. Digestion 20: 145-150, 1980.

233. Powell-Jackson PR, Tredger JM, Williams R: Hepatotoxicity to sodium valproate: A review. Gut 25: 673-681, 1984.

234. Punukollu RC, Kumar S, Mullen KD: Quinine hepatotoxicity. An underrecognized or rare phenomenon? Arch Intern Med 150: 1112-1113, 1990.

235. Quigley EMM, Marsh MN, Shaffer JL, Markin RS: Hepatobiliary complications of total parenteral nutrition. Gastroenterology 104: 286-301, 1993.

236. Rabinovitz M, Van Thiel DH: Hepatotoxicity of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 87: 1696-1704, 1992.

237. Rader JI, Calvert RJ, Hathcock JN: Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 92: 77-81, 1992.

238. Rahmat J, Gelfand RL, Gelfand MC, et al: Captopril-associated cholestatic jaundice. Ann Intern Med 102: 56-58, 1985.

239. Ramalho H, Terra E, Cartapatti E, et al: Hepatotoxicity of azathioprine in renal transplant recipients. Transplant Proc 21: 1716-1717, 1989.

240. Rank JM, Olson RC: Reversible cholestatic hepatitis caused by acetohexamide. Gastroenterology 96: 1607-1608, 1989.

241. Read AE, Weisner RH, LaBrecque DR, et al: Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 104: 651-655, 1986.

242. Reddy KR, Brillant P, Schiff ER: Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology 96: 1135-1137, 1989.

243. Rex D, Lumeng L, Eble J, Rex L: Intrahepatic cholestasis and sicca complex after thiobendazole. Report of a case and review of the literature. Gastroenterology 85: 718-721, 1983.

244. Reyes H: The enigma of intrahepatic cholestasis of pregnancy: Lesson from Chile. Hepatology 2: 87-96, 1982.

245. Reynolds R, Lloyd DA, Slinger RP: Cholestatic jaundice induced by flurazepam hydrochloride. Can Med Assoc J 124: 893-894, 1981.

246. Ribe D, Benkov KJ, Thung S, et al: Fatal massive hepatic necrosis: A probable hypersensitivity reaction to sulfasalazine. Am J Gastroenterol 81: 205-208, 1986.

247. Rigas B, Rosenfeld LE, Barwick KW, et al: Amiodarone hepatotoxicity. A clinicopathologic study of five patients. Ann Intern Med 104: 348-351, 1986.

248. Rigauts HD, Selleslag DL, Van Eyken PL, et al: Erythromycin-induced hepatitis: simulator of malignancy. Radiology 169: 661-662, 1988.

249. Rodman JS, Deutsch DJ, Gutman SI: Methyldopa hepatitis. A report of six cases and review of the literature. Am J Med 60: 941-948, 1976.

250. Roenigk HH Jr, Auerbach R, Mailbach HI, Weinstein GD: Methotrexate guidelines -- revised. J Am Acad Dermatol 6: 142-155, 1982.

251. Roenigk HH Jr, Bergfeld WF, St. Jacques R, et al: Hepatotoxicity of methotrexate in the treatment of psoriasis. Arch Dermatol 103: 250-261, 1971.

252. Rollins BJ: Hepatic veno-occlusive disease. Am J Med 81: 297-306, 1986.

253. Rooks JB, Ory HW, Ishak KG, et al: Epidemiology of hepatocellular adenoma: The role of oral contraceptive use. JAMA 242: 644-648, 1979.

254. Rotmensch HH, Leiser A, Dan M, et al: Evaluation of prajmalium-induced cholestasis by immunologic tests. Arch Intern Med 141: 1797-1801, 1981.

255. Rotmensch HH, Yust I, Siegman-Igra Y, et al: Granulomatous hepatitis: A hypersensitivity response to procainamide. Ann Intern Med 89: 646-647, 1978.

256. Roy AK, Mahoney HC, Levine RA: Phenytoin-induced chronic hepatitis. Dig Dis Sci 38: 740-742, 1993.

257. Roy MA, Nugent FW, Aretz HT: Micronodular cirrhosis after thiabendazole. Dig Dis Sci 34: 938-941, 1989.

258. Ruiz Del Arbol L, Moreira V, Moreno A, et al: Bridging hepatic necrosis associated with cimetidine. Am J Gastroenterol 74: 267-269, 1980.

259. Russell RI, Allan JG, Patrick R: Active chronic hepatitis after chlorpromazine ingestion. Br Med J 1: 655-656, 1973.

260. Russell RM, Boyer JL, Bagheri SA, Hruban Z: Hepatic injury from chronic hypervitamosis A resulting in portal hypertension and ascites. N Engl J Med 291: 435-440, 1974.

261. Sallen MK, Efusy ME, Kniaz JL, Wolfson PM: Streptokinase-induced hepatic dysfunction. Am J Gastroenterol 78: 523-524, 1983.

262. Sarachek NS, London RL, Matulewicz TJ: Diltiazem and granulomatous hepatitis. Gastroenterology 88: 1260-1262, 1985.

263. Scheuer PJ, Summerfield JA, Lal S, Sherlock S: Rifampicin hepatitis. A clinical and histological study. Lancet 1: 421-425, 1974.

264. Schneider HL, Hornbach KD, Kniaz JL, Efrusy ME: Chlorpropamide hepatotoxicity: Report of a case and review of the literature. Am J Gastroenterol 79: 721-724, 1984.

265. Scully LJ, Clarke D, Barr RJ: Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 38: 744-751, 1993.

266. Seaman WE, Ishak KG, Plotz PH: Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann Intern Med 80: 1-8, 1974.

267. Seeff LB, Cuccherini BA, Zimmerman HJ, et al: Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Intern Med 104: 399-404, 1986.

268. Seki K, Minami Y, Nishikawa M, et al: "Nonalcoholic steatohepatitis" induced by massive doses of synthetic estrogens. Gastroenterol Jpn 18: 197-203, 1983.

269. Shah IA, Brandt H: Halothane-associated granulomatous hepatitis. Digestion 28: 245-249, 1983.

270. Shapiro PA, Antonioli DA, Peppercorn MA: Barbiturate-induced submassive hepatic necrosis. Report of a case and review of the literature. Am J Gastroenterol 74: 270-273, 1980.

271. Sharp JR, Ishak KG, Zimmerman HJ: Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 92: 14-19, 1980.

272. Shaw DR, Misan GM, Johnson RD: Nifedipine hepatitis. Aust NZ J Med 17: 447-448, 1987.

273. Shepherd NA, Dawson AM, Crocker PR, et al: Granular cells as a marker of early amiodarone hepatotoxicity: A pathological and analytical study. J Clin Pathol 40: 418-423, 1987.

274. Shepherd P, Harrison DJ: Idiopathic portal hypertension associated with cytotoxic drugs. J Clin Pathol 43: 206-210, 1990.

275. Sherlock S: The spectrum of hepatotoxicity due to drugs. Lancet 2: 440-444, 1986.

276. Shuck J, Shen S, Owensby L, et al: Spironolactone hepatitis in primary hyperaldosteronism. Ann Intern Med 95: 708-710, 1981.

277. Simon JB, Manley PN, Brien JF, Armstrong PW: Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 311: 167-172, 1984.

278. Sippel PJ, Agger WA: Nitrofurantoin-induced granulomatous hepatitis. Urology 18: 177-178, 1981.

279. Snyder S: Fluphenazine jaundice. Report of a case. Am J Gastroenterol 73: 336-340, 1980.

280. Solis-Herruzo JA, Castellano G, Colina F, et al: Hepatic injury in the toxic epidemic syndrome caused by ingestion of adulterated cooking oil (Spain, 1981). Hepatology 4: 131-139, 1984.

281. Solis-Herruzo JA, Vidal JV, Colina F, et al: Clinico-biochemical evolution and late hepatic lesions in the toxic oil syndrome. Gastroenterology 93: 558-568, 1987.

282. Spechler SJ, Sperber H, Doos WG, Koff RS: Cholestasis and toxic epidermal necrolysis associated with phenytoin sodium ingestion: The role of bile duct injury. Ann Intern Med 95: 455-456, 1981.

283. Spitz RD, Keren DF, Boitnott JK, Maddrey WC: Bridging hepatic necrosis. Etiology and prognosis. Am J Dig Dis 23: 1076-1078, 1978.

284. Starko KM, Mullick FG: Hepatic and cerebral pathology findings in children with fatal salicylate intoxication: Further evidence for a causal relationship between salicylate and Reye's syndrome. Lancet 1: 326-328, 1983.

285. Steele MA, Burk RF, DesPrez RM: Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 99: 465-471, 1991.

286. Sterneck M, Wiesner R, Ascher N, et al: Azathioprine hepatotoxicity after liver transplantation. Hepatology 14: 806-810, 1991.

287. Stevenson RN, Nayani TH, Davies JR: Acute hepatic dysfunction following parenteral amiodarone administration. Postgrad Med J 65: 707-709, 1989.

288. Stoel I, Hagemeijer F: Aprindine: A review. Eur Heart J 1: 147-156, 1980.

289. Stricker BHC, Biour M, Wilson JHP: Individual agents: drugs. In Stricker BHC (ed): Drug-induced Hepatic Injury, 2nd ed. Amsterdam, 1992, Elsevier Science Publishers.

290. Stricker BHC, Blok APR, Desmet VJ: Pathology of drug-induced hepatic injury. In Stricker BHC (ed): Drug-induced Hepatic Injury, 2nd ed. Amsterdam, 1992, Elsevier Science Publishers.

291. Stricker BHC, Blok APR, Babany G, Benhamou J-P: Fibrin-ring granulomas and allopurinol. Gastroenterology 96: 1199-1203, 1989.

292. Stricker BHC, Blok APR, Bronkhorst FB: Glafenine-associated hepatic injury. Analysis of 38 cases and review of the literature. Liver 6: 63-70, 1986.

293. Stricker BHC, Blok APR, Bronkhorst FB, et al: Ketoconazole-associated hepatic injury. A clinicopathologic study of 55 cases. J Hepatol 3: 399-406, 1986.

294. Stricker BHC, Blok APR, Claas FHJ, et al: Hepatic injury associated with the use of nitrofurans: A clinicopathologic study of 52 reported cases. Hepatology 8: 599-606, 1988.

295. Stricker BHC, Van den Broek JW, Keuning J, et al: Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (Augmentin). Dig Dis Sci 34: 1576-1580, 1989.

296. Stromeyer FW, Ishak KG: Nodular transformation (nodular "regenerative" hyperplasia) of the liver: A clinicopathologic study of 30 cases. Hum Pathol 12: 60-71, 1981.

297. Suchy FJ, Balistreri WF, Buchino JJ, et al: Acute hepatic failure associated with the use of sodium valproate. A report of two cases. N Engl J Med 300: 962-966, 1979.

298. Swank LA, Chejfec G, Nemchausky BA: Allopurinol-induced granulomatous hepatitis with cholangitis and a sarcoid-like reaction. Arch Intern Med 138: 997-998, 1978.

299. Takegoshi K, Nakanuma Y, Ohta M, et al: Light and electron microscopic study of the liver in paraquat poisoning. Liver 8: 330-336, 1988.

300. Tanaka K, Kean EA, Johnson B: Jamaican vomiting disease. Biochemical investigation of two cases. N Engl J Med 295: 461-467, 1976.

301. Taxy JB: Peliosis: A morphologic curiosity becomes an iatrogenic problem. Hum Pathol 9: 331-340, 1978.

302. Tedesco FJ, Mills LR: Diazepam (Valium) hepatitis. Dig Dis Sci 27: 470-472, 1982.

303. Teychenne PF, Jones EA, Ishak KG, Calne DB: Hepatocellular injury with distinctive mitochondrial changes induced by lergotrile mesylate: A dopaminergic ergot derivative. Gastroenterology 76: 575-583, 1979.

304. Thaler H: Fatty change. Baillière's Clin Gastroenterol 2: 453-462, 1988.

305. Thies PW, Dull WL: Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis. Inadvertent rechallenge. Arch Intern Med 144: 1691-1692, 1984.

306. Thomas LB, Popper H, Berk PD, et al: Vinyl-chloride-induced liver disease. From idiopathic portal hypertension (Banti's syndrome) to angiosarcoma. N Engl J Med 292: 17-22, 1975.

307. Toft E, Vyberg M, Therkelsen K: Diltiazem-induced granulomatous hepatitis. Histopathology 18: 474-475, 1991.

308. Toghill PJ, Smith PG, Benton P, et al: Methyldopa liver damage. Br Med J 3: 545-548, 1974.

309. Tolman KG, Clegg DO, Lee RG, Ward JR: Methotrexate and the liver. J Rheumatol 12 (suppl 12): 29-34, 1985.

310. Touloukian J, Kaplowitz N: Halothane-induced hepatic disease. Semin Liv Dis 1: 134-142, 1981.

311. Tran A, Housset C, Boboc B, et al: Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. J Hepatol 12: 36-39, 1991.

312. Utili R, Boitnott JK, Zimmerman HJ: Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 72: 610-616, 1977.

313. Valla D, Benhamou J-P: Drug-induced vascular and sinusoidal lesions of the liver. Baillière's Clin Gastroenterol 2: 481-500, 1988.

314. Valla D, Le MG, Poynard T, et al: Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 90: 807-811, 1986.

315. van de Merwe J, van Blankenstein M, Wilson JHP: Intrahepatic cholestasis induced by phenylbutazone. Digestion 22: 317-320, 1981.

316. van Erpecum KJ, Janssens AR, Kreuning J, et al: Generalized peliosis hepatis and cirrhosis after long-term use of oral contraceptives. Am J Gastroenterol 83: 572-575, 1988.

317. Van Steenbergen W, Vanstapel MJ, Desmet V, et al: Cimetidine-induced liver injury. Report of three cases. J Hepatol 1: 359-368, 1981.

318. Vanderstigel M, Zafrani ES, Lejonc JL, et al: Allopurinol hypersensitivity as a cause of hepatic fibrin-ring granulomas. Gastroenterology 90: 188-190, 1986.

319. Vazquez JJ, Pardo-Mindan J: Liver cell injury (body similar to Lafora's) in alcoholics treated with disulfiram (Antabuse). Histopathology 3: 377-384, 1979.

320. Verhamme M, Ramboer C, Van de Bruaene P, et al: Cholestatic hepatitis due to amoxycillin/clavulanic acid preparation. J Hepatol 9: 260-264, 1989.

321. Victorino MM, Silveira JCB, Baptista A, et al: Jaundice associated with naproxen. Postgrad Med J 56: 368-370, 1980.

322. Victorino RM, Maria VA, Correia AP, de-Moura C: Floxacillin-induced cholestatic hepatitis with evidence of lymphocyte sensitization. Arch Intern Med 147: 987-988, 1987.

323. Walker CO, Combes B: Biliary cirrhosis induced by chlorpromazine. Gastroenterology 51: 631-640, 1966.

324. Wanless IR, Dore S, Gopinath N, et al: Histopathology of cocaine hepatotoxicity. Report of four patients. Gastroenterology 98: 497-501, 1990.

325. Weill BJ, Menkes CJ, Cormier C, et al: Hepatocellular carcinoma after danazol therapy. J Rheumatol 15: 1447-1449, 1988.

326. Wepler W, Opitz K: Histologic changes in the liver biopsy in Amanita phylloides intoxication. Hum Pathol 3: 249-254, 1972.

327. White LB, Detarnowsky GO, Mir JA, Layden TJ: Hepatotoxicity following enflurane anesthesia. Dig Dis Sci 26: 466-469, 1981.

328. Whitington PF: Cholestasis associated with total parenteral nutrition in infants. Hepatology 5: 693-696, 1985.

329. Whittaker SJ, Amar JN, Wanless IR, Heathcote J: Sulindac hepatitis. Gut 23: 875-877, 1982.

330. Williams CN, Malatjalian DA: Severe penicillin-induced cholestasis in a 91-year-old woman. Dig Dis Sci 26: 470-473, 1981.

331. Williams SJ, Ruppin DC, Grierson JM, et al: Carbamazepine hepatitis: The clinicopathological spectrum. J Gastroenterol Hepatol 1: 159-163, 1986.

332. Wilkinson SP, Portmann B, Williams R: Hepatitis from dantrolene sodium. Gut 20: 33-36, 1979.

333. Wilson FM, Belamaric J, Lauter CB, Lerner AM: Anicteric carbenicillin hepatitis. Eight episodes in four patients. JAMA 232: 818-821, 1975.

334. Winkler K, Poulsen H: Liver disease with periportal sinusoidal dilatation. A possible complication to contraceptive steroids. Scand J Gastroenterol 10: 699-704, 1975.

335. Wolfe BM, Walker BK, Shaul DB, et al: Effect of total parenteral nutrition on hepatic histology. Arch Surg 123: 1084-1090, 1988.

336. Zafrani ES, Bernuau D, Feldmann G: Peliosis-like ultrastructural changes of the hepatic sinusoids in human chronic hypervitaminosis A: Report of three cases. Hum Pathol 15: 1166-1170, 1984.

337. Zafrani ES, Berthelot P: Sodium valproate in the induction of unusual hepatotoxicity. Hepatology 2: 591-597, 1982.

338. Zafrani ES, Ishak KG, Rudzki C: Cholestatic and hepatocellular injury associated with erythromycin esters. Report of nine cases. Am J Dig Dis 24: 385-396, 1979.

339. Zafrani ES, Pinaudeau Y, Dhumeaux D: Drug-induced vascular lesions of the liver. Arch Intern Med 143: 495-502, 1983.

340. Zimmerman HJ: Effects of aspirin and acetaminophen on the liver. Arch Intern Med 141: 333-342, 1981.

341. Zimmerman HJ: Hepatotoxic effects of oncotherapeutic agents. Prog Liv Dis 8: 621-642, 1986.

342. Zimmerman HJ: Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals in the Liver. New York, 1978, Appleton-Century-Crofts.

343. Zimmerman HJ, Ishak KG: Valproate-induced hepatic injury. Analysis of 23 fatal cases. Hepatology 2: 591-597, 1982.

344. Zimmerman HJ, Lewis JH: Drug-induced cholestasis. Med Toxicol 2: 112-160, 1987.

345. Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC: Tricrynafen-associated hepatic injury: Analysis of 340 cases. Hepatology 4: 315-323, 1984.

346. Zitelli BJ, Alexander J, Taylor S, et al: Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). Ann Intern Med 106: 393-395, 1987.